Literature DB >> 27497988

Thioredoxin-interacting protein regulates lipid metabolism via Akt/mTOR pathway in diabetic kidney disease.

Chunyang Du1, Ming Wu2, Huan Liu3, Yunzhuo Ren4, Yunxia Du2, Haijiang Wu2, Jinying Wei2, Chuxin Liu3, Fang Yao2, Hui Wang2, Yan Zhu5, Huijun Duan6, Yonghong Shi7.   

Abstract

Abnormal lipid metabolism contributes to the renal lipid accumulation, which is associated with diabetic kidney disease, but its precise mechanism remains unclear. The growing evidence demonstrates that thioredoxin-interacting protein is involved in regulating cellular glucose and lipid metabolism. Here, we investigated the effects of thioredoxin-interacting protein on lipid accumulation in diabetic kidney disease. In contrast to the diabetic wild-type mice, the physical and biochemical parameters were improved in the diabetic thioredoxin-interacting protein knockout mice. The increased renal lipid accumulation, expression of acetyl-CoA carboxylase, fatty acid synthase and sterol regulatory element binding protein-1, and phosphorylated Akt and mTOR associated with diabetes in wild-type mice was attenuated in diabetic thioredoxin-interacting protein knockout mice. Furthermore, thioredoxin-interacting protein knockout significantly increased the expression of peroxisome proliferator-activated receptor-α, acyl-coenzyme A oxidase 1 and carnitine palmitoyltransferaser 1 in diabetic kidneys. In vitro experiments, using HK-2 cells, revealed that knockdown of thioredoxin-interacting protein inhibited high glucose-mediated lipid accumulation, expression of acetyl-CoA carboxylase, fatty acid synthase and sterol regulatory element binding protein-1, as well as activation of Akt and mTOR. Moreover, knockdown of thioredoxin-interacting protein reversed high glucose-induced reduction of peroxisome proliferator-activated receptor-α, acyl-coenzyme A oxidase 1 and carnitine palmitoyltransferaser 1 expression in HK-2 cells. Importantly, blockade of Akt/mTOR signaling pathway with LY294002, a specific PI3K inhibitor, replicated these effects of thioredoxin-interacting protein silencing. Taken together, these data suggest that thioredoxin-interacting protein deficiency alleviates diabetic renal lipid accumulation through regulation of Akt/mTOR pathway, thioredoxin-interacting protein may be a potential therapeutic target for diabetic kidney disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Akt/mTOR; Diabetic nephropathy; Lipid accumulation; PPARα; SREBP-1; TXNIP

Mesh:

Substances:

Year:  2016        PMID: 27497988     DOI: 10.1016/j.biocel.2016.08.006

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  10 in total

Review 1.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

2.  Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR) function during oxidative stress in cardiomyocytes.

Authors:  Shin-Ichi Oka; Tsuyoshi Hirata; Wataru Suzuki; Daichi Naito; Yanbin Chen; Adave Chin; Hiroaki Yaginuma; Toshiro Saito; Narayani Nagarajan; Peiyong Zhai; Santosh Bhat; Kevin Schesing; Dan Shao; Yoko Hirabayashi; Junji Yodoi; Sebastiano Sciarretta; Junichi Sadoshima
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

3.  A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis.

Authors:  Guideock Kwon; Md Jamal Uddin; Gayoung Lee; Songling Jiang; Ahreum Cho; Jung Hwa Lee; Sae Rom Lee; Yun Soo Bae; Sung Hwan Moon; Soo Jin Lee; Dae Ryong Cha; Hunjoo Ha
Journal:  Oncotarget       Date:  2017-06-16

4.  High Glucose Promotes CD36 Expression by Upregulating Peroxisome Proliferator-Activated Receptor γ Levels to Exacerbate Lipid Deposition in Renal Tubular Cells.

Authors:  Lei Feng; Chengwu Gu; Yanxia Li; Jiasui Huang
Journal:  Biomed Res Int       Date:  2017-04-12       Impact factor: 3.411

5.  FOXO1 Overexpression Attenuates Tubulointerstitial Fibrosis and Apoptosis in Diabetic Kidneys by Ameliorating Oxidative Injury via TXNIP-TRX.

Authors:  Linlin Ji; Qingzhu Wang; Fengjuan Huang; Tingting An; Feng Guo; Yanyan Zhao; Yang Liu; Yanyan He; Yi Song; Guijun Qin
Journal:  Oxid Med Cell Longev       Date:  2019-03-06       Impact factor: 6.543

Review 6.  The Emerging Role of TXNIP in Ischemic and Cardiovascular Diseases; A Novel Marker and Therapeutic Target.

Authors:  Alison Domingues; Julia Jolibois; Perrine Marquet de Rougé; Valérie Nivet-Antoine
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

Review 7.  Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.

Authors:  Haruka Tsubaki; Ikuo Tooyama; Douglas Gordon Walker
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

8.  D-Mannose Regulates Hepatocyte Lipid Metabolism via PI3K/Akt/mTOR Signaling Pathway and Ameliorates Hepatic Steatosis in Alcoholic Liver Disease.

Authors:  Mengyao Hu; Yu Chen; Fan Deng; Bo Chang; Jialiang Luo; Lijun Dong; Xiao Lu; Yi Zhang; Zhengliang Chen; Jia Zhou
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

9.  Blocking REDD1/TXNIP Complex Ameliorates HG-Induced Renal Tubular Epithelial Cell Apoptosis and EMT through Repressing Oxidative Stress.

Authors:  Lin Mu; Nan Chen; Yakun Chen; Zhifen Yang; Huandi Zhou; Shan Song; Yonghong Shi
Journal:  Int J Endocrinol       Date:  2022-09-21       Impact factor: 2.803

Review 10.  GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy.

Authors:  Yi Zuo; Li Chen; Huiping Gu; Xiaoyun He; Zhen Ye; Zhao Wang; Qixiang Shao; Caiping Xue
Journal:  Expert Rev Mol Med       Date:  2021-12-27       Impact factor: 5.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.